Jeremy Bender Day One Biopharmaceuticals, Inc. (DAWN) insider trading activity

Jeremy Bender is CHIEF EXECUTIVE OFFICER of Day One Biopharmaceuticals, Inc.. Currently has a direct ownership of 145,737 shares of DAWN, which is worth approximately $1.02 Million. The most recent transaction as insider was on Feb 15, 2023, when has been sold 8,312 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 146K

13.84% 3M change

77.74% 12M change

Total Value Held $1.02 Million

Jeremy Bender Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Date	Transaction	Value	Shares Traded	Shares Held	Form
Feb 15 2023	BUY Exercise of conversion of derivative security	-	8,312 Added 0.69%	1,189,798 Common Stock
Jan 23 2023	SELL Open market or private sale	$275,000 $22.0 p/Share	12,500 Reduced 1.05%	1,181,486 Common Stock
Dec 21 2022	SELL Open market or private sale	$254,000 $20.32 p/Share	12,500 Reduced 1.04%	1,192,424 Common Stock
Nov 21 2022	SELL Open market or private sale	$263,250 $21.06 p/Share	12,500 Reduced 1.03%	1,204,924 Common Stock
Nov 16 2022	SELL Open market or private sale	$32,468 $21.46 p/Share	1,513 Reduced 0.12%	1,217,424 Common Stock
Nov 15 2022	BUY Exercise of conversion of derivative security	-	3,562 Added 0.29%	1,218,937 Common Stock
Nov 01 2022	SELL Open market or private sale	$250,375 $20.03 p/Share	12,500 Reduced 1.02%	1,215,375 Common Stock
Oct 03 2022	SELL Open market or private sale	$250,625 $20.05 p/Share	12,500 Reduced 1.01%	1,227,875 Common Stock
Sep 01 2022	SELL Open market or private sale	$293,375 $23.47 p/Share	12,500 Reduced 1.0%	1,240,375 Common Stock
Sep 01 2022	SELL Open market or private sale	$293,375 $23.47 p/Share	12,500 Reduced 1.0%	1,240,375 Common Stock
Aug 16 2022	SELL Open market or private sale	$97,313 $24.31 p/Share	4,003 Reduced 0.32%	1,252,875 Common Stock
Aug 15 2022	BUY Exercise of conversion of derivative security	-	10,686 Added 0.84%	1,256,878 Common Stock
Aug 04 2022	SELL Open market or private sale	$250,000 $20.0 p/Share	12,500 Reduced 0.99%	1,246,192 Common Stock
Jul 18 2022	SELL Open market or private sale	$52,000 $20.0 p/Share	2,600 Reduced 0.21%	1,258,692 Common Stock
Jul 08 2022	SELL Open market or private sale	$35,900 $20.0 p/Share	1,795 Reduced 0.14%	1,261,292 Common Stock
Jul 05 2022	SELL Open market or private sale	$17,140 $20.0 p/Share	857 Reduced 0.07%	1,263,087 Common Stock
Jul 01 2022	SELL Open market or private sale	$34,920 $20.0 p/Share	1,746 Reduced 0.14%	1,263,944 Common Stock

Also insider at

FUSN

Fusion Pharmaceuticals Inc. Healthcare

MREO

Mereo Biopharma Group plc Healthcare

Jeremy Bender

CHIEF EXECUTIVE OFFICER

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DAWN shares.

Notify only if

Value

Any

Insider Trading

Get notified when an Day One Biopharmaceuticals, Inc. insider buys or sells DAWN shares.

Notify only if

Operation

Any

Value

Any

Type

P - Open market or private purchase×

S - Open market or private sale×

V - Transaction voluntarily reported earlier than required×

A - Grant, award, or other acquisition×

D - Sale (or disposition) back to the issuer×

F - Payment of exercise price or tax liability×

I - Discretionary transaction×

M - Exercise of conversion of derivative security×

C - Conversion of derivative security×

E - Expiration of short derivative position×

H - Expiration (or cancellation) of long derivative position with value received×

O - Exercise of out-of-the-money derivative securities×

X - Exercise of in-the-money or at-the-money derivatives securities×

G - Bona fide gift×

L - Small Acquisition×

W - Acquisition or disposition by will or laws×

Z - Deposit into or withdrawal from voting trust×

J - Other acquisition or disposition×

K - Transaction in equity swap or similar instrument×

U - Disposition due to a tender of shares in a change of control transaction×

20 item(s) selected

News

Receive news related to Day One Biopharmaceuticals, Inc.

Track Activities on DAWN

Account